Evaluating the effects of certain drugs on liver fibrosis
Official title: Clinical Study Evaluating the Efficacy of Renin Angiotensin System Inhibitors on the Extent of Liver Fibrosis in Patients With Chronic Hepatitis C
Run by Tanta University · NCT03770936 · Data updated 2026-11-12
This study is testing whether the medications Candesartan and Ramipril can help improve liver health in people with liver fibrosis caused by chronic hepatitis C.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 20 Years and up |
| Sex | All |
| Enrollment | 45 (estimated) |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Tanta) |
| Status | Recruiting |
| Started | October 1, 2018 |
| Main results expected | October 2026 |
| Study ends | November 2027 |
| Registry record updated | December 10, 2018 |
| Trial ID | NCT03770936 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals diagnosed with chronic hepatitis C who are experiencing liver fibrosis.
✕Probably not a fit
Patients with acute hepatitis or thalassemia may not receive any benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the impact of two medications, Candesartan and Ramipril, on patients suffering from liver fibrosis due to chronic hepatitis C. It is designed as a Phase 3 interventional trial, focusing on assessing the efficacy of these drugs in improving liver health. The study aims to gather comprehensive data on how these treatments can influence the progression of liver fibrosis.
Why it matters
Potential benefit: If successful, this study could provide new therapeutic options for patients with liver fibrosis, potentially improving their liver function and overall health.
How similar studies have gone: There is limited information on the success of similar studies, making this approach somewhat novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * chronic hepatitis C Exclusion Criteria: * Acute hepatitis * Thalassemia
Where it's running
-
Sherief Abd-Elsalam
Tanta, Egypt Recruiting
Study contacts
- Principal investigator: Gamal El-azab, Prof — Clinical pharmacy Department- Tanta University
- Study coordinator: Sherief Abd-Elsalam, Ph D
- Email: sheriefabdelsalam@yahoo.com
- Phone: 00201147773440
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating atorvastatin's effect on liver cancer risk in patients with advanced fibrosis
This study is testing if taking atorvastatin can lower the risk of liver cancer in adults with advanced liver fibrosis who are at high risk for developing the disease.
-
Improving early diagnosis of liver disease using integrated diagnostics
This study is trying to improve how quickly and accurately liver disease is diagnosed by combining different tests and information from around 750 patients who are at risk or have abnormal liver blood tests.
-
Understanding liver damage and heart health in patients with NAFLD
This study looks at how liver damage affects heart health in people with non-alcoholic fatty liver disease to see what factors might predict worsening liver problems.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.